Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...
One of this year's top articles on cost and coverage highlights that the average American can afford a maximum of $97 in ...
Of the top news articles, Vertex Pharmaceuticals' suzetrigine garnered much attention as it's a promising new class of pain ...
Historically, healthcare organizations have considered the contact center to be a cost center, a communications platform for ...
Take a look at the best performing print articles of 2024. This year's top article spotlights the surge of mRNA vaccines ...
Take a look at the best performing print articles of 2024. This year's top article spotlights the surge of mRNA vaccines ...
Kamilia Smith, MD, FACOG, NCMP, discusses how societal stigma and cultural misconceptions about menopause, combined with ...
Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...
Anna Podolanczuk, M.D., M.S., discusses how key epidemiological trends in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including changes in incidence and prevalence, ...
Up to half of obstructive sleep apnea patients taking Zepbound had no symptoms after one year of treatment, averaging 25 ...
Tryngolza is once-monthly, subcutaneous RNA-targeted therapy and is expected to be available by the end of the year with a ...
The boxed warning follows a safety warning the FDA issued in September about the risk of liver injury from the use of Veozah ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback